Mollugo oppositifolia 提取物抑制胆碱酯酶与β-分泌酶的体外研究
本研究通过体外实验评估 M. oppositifolia 提取物对乙酰胆碱酯酶(AChE)、丁酰胆碱酯酶(BChE)和β-分泌酶的抑制活性,并检测其安全性及抗氧化能力。结果显示提取物对 BChE 选择性更高(IC50=278.23±1.89 μg/ml),对β-分泌酶 IC50 为 173.93 μg/ml,且体外安全性指标在可接受范围,提示其具有抗阿尔茨海默病潜力。
要点
- 提取物对 BChE 抑制活性强于 AChE(IC50 分别为 278.23 与 322.87 μg/ml)。
- β-分泌酶抑制 IC50 为 173.93 μg/ml,提示多靶点抗 AD 潜力。
- 体外安全性:HepG2 细胞 CC50 965.45 μg/ml,铅含量 0.02 ppm 符合 WHO 限值。
核心结论
- M. oppositifolia 提取物具有体外抗阿尔茨海默病潜力,表现为对 BChE 和β-分泌酶的多靶点抑制。
研究设计与样本
- 体外实验研究:测试植物提取物对 AChE、BChE、β-分泌酶的抑制活性,并评估 CYP450 同工酶抑制、HepG2 细胞毒性、重金属含量及抗氧化能力。
- 采用 UPLC-QTOF-MS/MS 鉴定植物代谢物,并用 AutoDockTools 1.5.6 进行分子对接分析。
主要发现
- 提取物对 BChE 的 IC50 为 278.23±1.89 μg/ml,对 AChE 的 IC50 为 322.87±2.05 μg/ml,对β-分泌酶的 IC50 为 173.93 μg/ml。
- 提取物对 HepG2 细胞的 CC50 为 965.45±3.07 μg/ml;铅含量为 0.02±0.001,在 WHO 规定限值内。
- 对 CYP3A4 和 CYP2D6 的 IC50 分别为 477.03±2.01 μg/ml 和 249.65±2.46 μg/ml。
- 分子对接显示化合物 menthoside 在所有鉴定代谢物中对接分数最佳且最稳定。
关键数值与推荐
- BChE 抑制 IC50=278.23±1.89 μg/ml;AChE 抑制 IC50=322.87±2.05 μg/ml;β-分泌酶抑制 IC50=173.93 μg/ml。
- HepG2 细胞毒性 CC50=965.45±3.07 μg/ml;铅含量 0.02±0.001,低于 WHO 限值。
- CYP3A4 抑制 IC50=477.03±2.01 μg/ml;CYP2D6 抑制 IC50=249.65±2.46 μg/ml。
临床怎么用
- 该提取物显示体外多靶点抗 AD 相关酶抑制活性,但尚未提供临床剂量或体内有效性数据,不可直接用于临床处方。
- 体外安全性数据(CYP450 抑制、HepG2 毒性、重金属限量)可为后续体内研究设计提供参考。
局限性
- 研究仅为体外实验和计算机模拟,缺乏动物模型或人体试验验证。
- 未报告提取物的具体化学成分含量、实验重复次数及统计显著性细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mollugo oppositifolia Linn. is traditionally used in neurological complications. The study aimed to investigate in-vitro neuroprotective effect of the plant extracts through testing against acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and β-secretase linked to Alzheimer's disease (AD). To understand the safety aspects, the extracts were tested for CYP450 isozymes and human hepatocellular carcinoma cell (HepG2) inhibitory potential. The heavy metal contents were estimated using atomic absorption spectroscopy (AAS). Further, the antioxidant capacities as well as total phenolic content and total flavonoid content (TFC) were measured spectrophotometrically. UPLC-QTOF-MS/MS analysis was employed to identify phytometabolites present in the extract. The interactions of the ligands with the target proteins (AChE, BChE, and BACE-1) were studied using AutoDockTools 1.5.6. The results showed that M. oppositifolia extract has more selectivity towards BChE (IC50 = 278.23 ± 1.89 μg/ml) as compared to AChE (IC50 = 322.87 ± 2.05 μg/ml). The IC50 value against β-secretase was 173.93 μg/ml. The extract showed a CC50 value of 965.45 ± 3.07 μg/ml against HepG2 cells and the AAS analysis showed traces of lead 0.02 ± 0.001 which was found to be within the WHO prescribed limits. Moreover, the IC50 values against CYP3A4 (477.03 ± 2.01 μg/ml) and CYP2D6 (249.65 ± 2.46 μg/ml) isozymes justify the safety aspects of the extract. The in silico molecular docking analysis of the target enzymes showed that the compound menthoside was found to be the most stable and showed a good docking score among all the identified metabolites. Keeping in mind the multi-targeted drug approach, the present findings suggested that M. oppositifolia extract have anti-Alzheimer's potential.
引用
- Das B, Bhardwaj PK, Sharma N, et al. Evaluation of Mollugo oppositifolia Linn. as cholinesterase and β-secretase enzymes inhibitor. Front Pharmacol. 2023. PMID: 36686717. doi:10.3389/fphar.2022.990926
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。